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Testicular cancer has a peak incidence at around 30 years of age,
and it is the most common cancer in men under 35 years of age,
accounting for a third of all cancers in that age range (Adami et al,
1994). The age distribution is unusual among adult malignancies,
with almost 70% of cases arising in men under 40 years of age, and
only about 2% in men over 70 years of age. Incidence has increased
steadily in many developed countries over the last 50 years,
including the United Kingdom (Coleman et al, 1993; Richiardi et al,
2004). In men under 50 years of age, incidence has risen almost
two-fold in England and Wales in the last 30 years, but the increase
has been much smaller among older men (Quinn et al, 2001).
Age-standardised mortality was 1 per 100000 per year during the
1950s, and it rose slightly during the 1960s and 1970s. Advances in
the treatment of testicular cancer since the 1960s have had a
dramatic effect on survival (Coleman et al, 1999), and men born
during the 1950s and 1960s had substantially lower testicular cancer
mortality in the late 1970s and early 1980s than earlier birth
cohorts, despite the substantial rise in incidence (Quinn et al, 2001).
Cryptorchidism is one of the few known risk factors (Richiardi
et al, 2002). A positive family history also carries a higher risk, but
vasectomy has not been shown to increase risk (Møller et al, 1994).
Most testicular cancers are germ cell tumours, either seminoma
or non-seminoma. Seminomas arise from the sperm-producing
testicular germ cells, whereas non-seminoma germ cell tumours
include teratoma, choriocarcinoma and yolk sac tumours.
Seminomas are treated by surgical removal of the affected testicle
(orchiectomy) and adjuvant radiotherapy. Surgical treatment is
also effective with early stage teratomas. Orchiectomy alone cures
around 80% of testicular cancer patients (Dearnaley et al, 2006).
We analysed survival patterns for 18605 men diagnosed with
testicular cancer aged 15–99 years in England and Wales during
1986–1999 and followed up to 31 December 2001. Less than 5% of
tumour records had to be excluded from analysis: 2% because the
vital status was not known when data were extracted for analysis,
less than 2% because the testicular cancer either followed or was
synchronous with another primary malignancy, and about 1%
because the date of diagnosis was the same as the date of death
(‘zero survival’). Virtually all the tumours in the last category will
have been registered solely from a death certificate, from which the
date of diagnosis is unavailable, as very few men would be
expected to have died on the day of diagnosis, but the two
categories could not be reliably distinguished in the national data.
In total, 54% of tumours were seminomas, and 29% teratomas,
similar to the proportions seen in the late 1980s (50 and 30%).
Rare morphologic types included choriocarcinoma, trophoblastic
teratoma (1%), Leydig cell tumour (0.3%) and a few Sertoli cell
tumours. Although cryptorchidism is a known risk factor, less than
1% of tumours were recorded as having arisen in an undescended
testis.
SURVIVAL TRENDS
For men diagnosed during 1986–1990, relative survival was 96% at
1 year after diagnosis and 91% at both 5 and 10 years. Survival has
risen further with time, so that for men diagnosed during 1996–
1999, relative survival had reached 98% at 1 year after diagnosis
and 97% at 5 years (Table 1, Figure 1). Ten-year survival was
effectively the same as 5-year survival.
After adjustment for deprivation, the average increase every 5
years was 0.5% for 1-year survival and 1% for 5-year survival.
These trends are not statistically significant, but the small
increases in 1-, 5- and 10-year survival were consistent across
three time periods.
Short-term prediction of survival up to 10 years, derived from
hybrid analysis (Brenner and Rachet, 2004) of the conditional
survival probabilities actually observed among men alive at some
point during 2000–2001, suggests that survival will not increase
much further in the near future (Table 1). If the most recently
observed survival patterns were to persist unchanged for the rest of
the decade, men diagnosed in the first few years of the 21st century
may expect 10-year relative survival rates that approach 96%.
Survival rose substantially for older men during the 1990s, and
the huge decline in survival with age became less marked. Thus, 5-
year relative survival was over 90% for men diagnosed under the
age of 50 during the decade 1986–1995, but less than 70% for men
aged 70–79 years, and less than 40% for elderly men (80–99
years). For men aged 80–99 years diagnosed during 1996–1999,
however, 5-year survival had risen to 55% (data not tabulated).
DEPRIVATION
For men diagnosed during 1986–1990, relative survival up to 10
years after diagnosis was significantly lower, by 3–5%, among
*Correspondence: Professor MP Coleman;
E-mail: michel.coleman@lshtm.ac.uk
British Journal of Cancer (2008) 99, S80–S82
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $32.00
www.bjcancer.comthose in the most deprived group than those in the most affluent
group (Table 2, Figure 2). By the late 1990s, this deprivation gap in
survival at 1, 5 and 10 years had fallen to as little as 1%, and it was
only of borderline significance for 1-year survival.
Short-term predictions, based on hybrid analysis of the
probabilities observed during 2000–2001, suggest that the depriva-
tion gradient will remain small, of the order of  1% (Table 2).
COMMENT
Survival from testicular cancer is the highest for any malignancy
among adult males in England and Wales.
The gain in survival over the last 20 years has been little
short of remarkable. One-year and five-year survival for
men diagnosed in England and Wales during the early 1970s was
already 82 and 69%, respectively, but it rose to 95 and 89%,
respectively, for men diagnosed in the early 1980s, just a
decade later (Coleman et al, 1999). The data reported here
show that for men diagnosed in the late 1990s, short-term survival
was already approaching the theoretical maximum of 100%,
and even longer-term survival exceeded 95%, whereas period
analysis suggests that the increase is likely to continue, albeit
more slowly.
The increase in survival among the oldest men is not statistically
significant, and it concerns only a small minority of cases, but it
Table 1 Trends in relative survival (%) by time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Men 95.7 (95.1, 96.3) 97.2 (96.8, 97.6) 98.1 (97.7, 98.4) 0.5 ( 0.3, 1.3) 98.3 (97.7, 98.7)
5 years Men 91.4 (90.6, 92.2) 94.3 (93.6, 94.8) 96.5 (95.9, 97.0) 1.2 ( 0.2, 2.5) 96.3 (95.5, 97.0)
10 years Men 91.4 (90.6, 92.2) 94.0 (93.3, 94.6) 2.0 ( 0.5, 4.4) 95.5 (94.5, 96.3)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008).
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Figure 1 Relative survival (%) up to 10 years after diagnosis by calendar
period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001. Survival estimated with
cohort or complete approach (1986–1990, 1991–1995, 1996–1999) or
hybrid approach (2000–2001) (see Rachet et al, 2008).
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Figure 2 Trends in the deprivation gap in 5-year relative survival (%) by
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001.
Table 2 Trends in the deprivation gap in relative survival (%) by time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men  2.7** ( 4.3,  1.0)  1.5** ( 2.6,  0.5)  1.1* ( 2.1,  0.1) 0.8 ( 0.2, 1.8)  0.9 ( 2.1, 0.3)
5 years Men  4.7** ( 7.0,  2.4)  3.3** ( 5.0,  1.7)  1.3 ( 3.3, 0.8) 1.8* (0.2, 3.4)  1.5 ( 3.7, 0.6)
10 years Men  4.3** ( 6.6,  1.9)  3.6** ( 5.3,  1.8) 0.7 ( 2.2, 3.6)  1.2 ( 3.8, 1.4)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in the deprivation gap in survival every 5
years, adjusted for the underlying trend in survival (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po 0.01.
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to treatment of curative intent being offered to even the oldest men
with testicular cancer.
Relative survival at 10 years is now virtually identical to that
at 5 years, which itself is already more than 95%. This indicates
that, among men who survive 5 years, there is virtually no further
excess mortality over that of men in the general population, after
adjustment for age and deprivation. In other words, the data provide
strong public health evidence that 5-year survivors of testicular
cancer are now virtually all ‘cured’, because, taken as a group, their
mortality is no different from that of their peers in the general
population.
Coherence of national trends in incidence, survival and
mortality since the 1970s is striking. Despite rapidly rising
incidence, survival has risen and mortality has continued to fall.
This provides convincing evidence of the nation-wide impact of
the addition of platinum-based chemotherapy in the 1970s to early
diagnosis, surgery and radiotherapy.
Despite the fact that relative survival was very high for men in all
socioeconomic groups combined, there was still a significant
socioeconomic gradient in survival. This is so even after
adjustment for socioeconomic differences in the background risk
of death by the use of life tables that are specific for each
socioeconomic group.
The trend in overall survival now approaches 100%, and the
deprivation gap in survival has fallen commensurately, from 13%
or more for men diagnosed during the early 1970s to less than 5%
for men diagnosed during the late 1990s. This narrowing of the
deprivation gap appears to reflect a ‘ceiling’ effect, as there is little
room for any further increase in relative survival among the most
affluent group. Survival for the most affluent men diagnosed most
recently approaches 100%.
Despite the unquestionably dramatic improvement in survival,
men in the most deprived categories still only attain the relative
survival of the most affluent men with a time lag of at least
5 calendar years.
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